Truist Financial Corp Purchases New Stake in Dyadic International, Inc. (NASDAQ:DYAI)

Truist Financial Corp purchased a new stake in Dyadic International, Inc. (NASDAQ:DYAI) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 250,000 shares of the biotechnology company’s stock, valued at approximately $428,000. Truist Financial Corp owned approximately 0.84% of Dyadic International at the end of the most recent reporting period.

Separately, Inlet Private Wealth LLC bought a new stake in Dyadic International during the fourth quarter valued at $52,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Dyadic International in a research report on Thursday, November 14th.

Dyadic International Stock Up 1.5 %

Dyadic International stock opened at $1.42 on Wednesday. The company has a 50-day simple moving average of $1.60 and a 200-day simple moving average of $1.41. The firm has a market capitalization of $42.05 million, a P/E ratio of -6.18 and a beta of 0.89. The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15. Dyadic International, Inc. has a one year low of $0.93 and a one year high of $2.67.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.